AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintering temperatures above 1,650°C
Number of subjects: 198
Study 22358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sintering temperatures
Number of subjects: 198
Study 22358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintering temperatures
Number of subjects: 198
Study 22358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintering temperature exceeding 1,550°C
Number of subjects: 198
Study 21640249 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting Ready intervention
Number of subjects: 217
Study 19563648 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg BID, starting 24 h before the procedure
Number of subjects: 90
Study 19563648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16226012 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (algal oil providing 50 mg of DHA per kilogram per day for 6 months)
Number of subjects: 20
Study 16226012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16226012 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 20
Study 15087298 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP)
Number of subjects: 39
Study 15087298 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walk distance (6-MWD)
Number of subjects: 39
Study 11763897 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Plaque Remover
Number of subjects: 67
Study 11763897 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Plus electric toothbrush
Number of subjects: 67
Study 9270065 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume grafts (up to 20 mm3)
Number of subjects: 13
Study 9270065 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume grafts (approximately 24 mm3)
Number of subjects: 13
Study 8420684 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens (five different regimens)
Number of subjects: 383
Study 3510820 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol (1.30 mg six times a day)
Number of subjects: 10
Study 3510820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (plasma levels of 10-15 micrograms/ml)
Number of subjects: 10
Study 3510820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug therapy (metaproterenol + theophylline)
Number of subjects: 10
Study 3510820 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol-placebo
Number of subjects: 10
Study 3510820 — intervention group
Group type: COMPARATOR
Intervention: Theophylline-placebo
Number of subjects: 10
Study 3510820 — intervention group
Group type: COMPARATOR
Intervention: Placebo-placebo
Number of subjects: 10
Study 28894067 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment Education Program (EEP) for kidney transplant patients, conducted weekly for six weeks
Number of subjects: 53
Study 28894067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study 27039153 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR (CVC)
Number of subjects: 0
Study 27039153 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Compression only CPR (CCC)
Number of subjects: 0
Study 27039153 — intervention group
Group type: EXPERIMENTAL
Intervention: SL (shown the approximate location on the lower half of the sternum)
Number of subjects: 0
Study 27039153 — intervention group
Group type: EXPERIMENTAL
Intervention: 2F (2 finger-breadth proximal from xiphoid process)
Number of subjects: 0
Study 24576513 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) added to usual care
Number of subjects: 300
Study 24576513 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 300
Study 22321661 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 1119
Study 22321661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1119
Study 19497171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 25
Study 19497171 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 25
Study 17923611 — intervention group
Group type: COMPARATOR
Intervention: Absent hippocampal atrophy
Number of subjects: 323
Study 17923611 — intervention group
Group type: COMPARATOR
Intervention: Moderate hippocampal atrophy
Number of subjects: 323
Study 17923611 — intervention group
Group type: COMPARATOR
Intervention: Severe hippocampal atrophy
Number of subjects: 323
Study 17923611 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 323
Study 17923611 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE epsilon 4 allele
Number of subjects: 323
Study 17923611 — intervention group
Group type: EXPERIMENTAL
Intervention: General cognition
Number of subjects: 323
Study 17923611 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hippocampal atrophy
Number of subjects: 323
Study 15764050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound rated at 1 W/cm(2) with compressive therapy (Group A)
Number of subjects: 65
Study 15764050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound rated at 0.5 W/cm(2) with compressive therapy (Group B)
Number of subjects: 65
Study 15764050 — intervention group
Group type: COMPARATOR
Intervention: Topical pharmacological treatment (Group C)
Number of subjects: 65
Study 12198045 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate, 2.48 mmol, injected 20 s before propofol administration
Number of subjects: 0
Study 10536243 — intervention group
Group type: EXPERIMENTAL
Intervention: Witepsol H15 (fast drug-releasing suppository)
Number of subjects: 8
Study 10536243 — intervention group
Group type: COMPARATOR
Intervention: Witepsol W35 (slow drug-releasing suppository)
Number of subjects: 8
Study 7763215 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolutrol 0.15 g/100 mL (Ketsugo)
Number of subjects: 70
Study 7763215 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide lotion
Number of subjects: 70
Study 1689807 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (0.15 mg/kg)
Number of subjects: 28
Study 1689807 — intervention group
Group type: COMPARATOR
Intervention: placebo (normal saline)
Number of subjects: 28
Study 6106884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiotensin (100mg bupranolol, 10mg bemetizide, 20mg triamterene)
Number of subjects: 30
Study 31193584 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help intervention with chat support
Number of subjects: 311
Study 31193584 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help intervention without chat support
Number of subjects: 311
Study 31193584 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 311
Study 28714741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 34
Study 28714741 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 34
Study 27565521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes (PROs) and Socioeconomic Status (SES) before HCT
Number of subjects: 646
Study 27565521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplantation Cancer and Treatment Distress (CTXD)
Number of subjects: 646
Study 27565521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 646
Study 27565521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower attained education
Number of subjects: 646
Study 27565521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 646
Study 27565521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of employment before transplantation
Number of subjects: 646
Study 27565521 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried status
Number of subjects: 646
Study 24474520 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation technique using a standard stethoscope over the catheter insertion site after injecting 2 mL of NaCl 0.9% solution.
Number of subjects: 20
Study 24474520 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injections (control group) in the opposite arm.
Number of subjects: 20
Study 23346249 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment for another 7 days
Number of subjects: 30
Study 23346249 — intervention group
Group type: COMPARATOR
Intervention: No treatment for the next 7 days
Number of subjects: 30
Study 20922911 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg/daily)
Number of subjects: 80
Study 20922911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17327324 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 580
Study 17327324 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 580
Study 15654523 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and plication (RAP)
Number of subjects: 60
Study 15654523 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MM)
Number of subjects: 60
Study 11481363 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with breast cancer considering participation in clinical trials (33%)
Number of subjects: 545
Study 11481363 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about randomized trials
Number of subjects: 545
Study 11481363 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 545
Study 11481363 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for an active role in decision-making
Number of subjects: 545
Study 11481363 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive aspects of clinical trials
Number of subjects: 545
Study 11481363 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative aspects of clinical trials
Number of subjects: 545
Study 9442783 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide (3 times daily)
Number of subjects: 16
Study 9442783 — intervention group
Group type: COMPARATOR
Intervention: Oral acetazolamide 250 mg (single administration)
Number of subjects: 16
Study 7734461 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus frequent urine testing and acupuncture treatments
Number of subjects: 0
Study 7734461 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus frequent urine testing
Number of subjects: 0
Study 7734461 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 2556725 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4‐10 (1 mg)
Number of subjects: 20
Study 2556725 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 427 (200 micrograms)
Number of subjects: 20
Study 2556725 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 427 (60 micrograms)
Number of subjects: 20
Study 2556725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4367686 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-dihydro-1-isoquinolineacetamide hydrochloride (DIQA)
Number of subjects: 21
Study 4367686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29189579 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body exergaming (WBE)
Number of subjects: 25
Study 29189579 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 25
Study 28676252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 29
Study 28676252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25245776 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrambler therapy for up to ten daily 30‐min sessions
Number of subjects: 37
Study 23218575 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 425
Study 23218575 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 425
Study 21534651 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided exposure in situ (T+)
Number of subjects: 369
Study 21534651 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-prescribed exposure in situ (T-)
Number of subjects: 369
Study 21534651 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 369
Study 19950325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT) for 24 weeks, twice weekly
Number of subjects: 28
Study 19950325 — intervention group
Group type: COMPARATOR
Intervention: Control group (range of movement home exercise)
Number of subjects: 28
Study 16850327 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 24
Study 16850327 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg
Number of subjects: 24
Study 15478851 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor treatment for 4 weeks
Number of subjects: 50
Study 11532418 — intervention group
Group type: EXPERIMENTAL
Intervention: Longo stapled circumferential mucosectomy (LSCM)
Number of subjects: 80
Study 11532418 — intervention group
Group type: COMPARATOR
Intervention: Hospital Leopold Bellan (HLB) hemorrhoidectomy
Number of subjects: 80
Study 9407268 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant exposure with feedback (REF)
Number of subjects: 45
Study 9407268 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant exposure with no feedback (RENoF)
Number of subjects: 45
Study 9407268 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant exposure with feedback (IEF)
Number of subjects: 45
Study 9407268 — intervention group
Group type: COMPARATOR
Intervention: All groups (REF, RENoF, IEF)
Number of subjects: 45
Study 9407268 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects' report of exposure treatment undertaken at home
Number of subjects: 45
Study 7624106 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-sestamibi (MIBI) injection for SPET imaging
Number of subjects: 27
Study 7624106 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 27
Study 2693076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolamine oleate (Et)
Number of subjects: 50
Study 2693076 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol (Pl)
Number of subjects: 50
Study 627881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stimulus similarity task
Number of subjects: 30
Study 627881 — intervention group
Group type: COMPARATOR
Intervention: High stimulus similarity task
Number of subjects: 30
Study 627881 — intervention group
Group type: EXPERIMENTAL
Intervention: Introverts
Number of subjects: 30
Study 627881 — intervention group
Group type: EXPERIMENTAL
Intervention: Extroverts
Number of subjects: 30
Study 31175001 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib (60 mg orally once daily, with a 30 mg lead-in)
Number of subjects: 367
Study 31175001 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice including low-dose cytarabine, mitoxantrone, etoposide, and others)
Number of subjects: 367
Study 26692084 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (65 mg elemental magnesium) twice per day
Number of subjects: 40
Study 26692084 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice per day
Number of subjects: 40
Study 27429174 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo (EXP)
Number of subjects: 46
Study 27429174 — intervention group
Group type: COMPARATOR
Intervention: Pain-contingent treatment as usual (TAU)
Number of subjects: 46
Study 23328738 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 60
Study 23328738 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 60
Study 23328738 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 21328522 — intervention group
Group type: EXPERIMENTAL
Intervention: ¹²³I-MIBG
Number of subjects: 350
Study 21328522 — intervention group
Group type: COMPARATOR
Intervention: ¹³¹I-MIBG
Number of subjects: 350
Study 19333746 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberation in simulated juries (4-7 persons)
Number of subjects: 0
Study 17342074 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy yogurt preload beverage (YP: 500 ml, 1988 kJ for men; 375 ml, 1507 kJ for women)
Number of subjects: 54
Study 17342074 — intervention group
Group type: COMPARATOR
Intervention: No preload (NP)
Number of subjects: 54
Study 17342074 — intervention group
Group type: EXPERIMENTAL
Intervention: Active subjects
Number of subjects: 54
Study 17342074 — intervention group
Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 54
Study 15494230 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary amylase activity monitor using a testing-strip and optical analyzer measuring salivary amylase activity with a range of 0-200 kU/l within 150 s.
Number of subjects: 0
Study 15494230 — intervention group
Group type: EXPERIMENTAL
Intervention: Kraepelin psychodiagnostic test as a psychological stressor.
Number of subjects: 0
Study 11341354 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (LMS) at four different dose levels over 3 days
Number of subjects: 0
Study 11341354 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (LMS)
Number of subjects: 0
Study 11341354 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (LMS) in vitro analysis
Number of subjects: 0
Study 9004097 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-malignant non-proteinuric normo-creatininaemic hypertension
Number of subjects: 0
Study 9004097 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans with hypertension
Number of subjects: 0
Study 9004097 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign essential hypertension
Number of subjects: 0
Study 1858444 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pain diary
Number of subjects: 20
Study 1858444 — intervention group
Group type: COMPARATOR
Intervention: Conventional pain diary
Number of subjects: 20
Study 1858444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (NSAID)
Number of subjects: 20
Study 6343149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etretinate, 1 mg/kg b.w. for 8 weeks
Number of subjects: 5
Study 6343149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31234587 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified, milk-derived protein matrix (MBPM)
Number of subjects: 0
Study 31234587 — intervention group
Group type: COMPARATOR
Intervention: Control (maltodextrin, CON)
Number of subjects: 0
Study 28605730 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,200 mg/m2) and Vinorelbine (25 mg/m2) intravenously on days 1 and 8 every 3 weeks
Number of subjects: 42
Study 27025864 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coupling Control (OCC)
Number of subjects: 336
Study 27025864 — intervention group
Group type: COMPARATOR
Intervention: Blind coupling
Number of subjects: 336
Study 24880692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette Cues
Number of subjects: 40
Study 24880692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Cues
Number of subjects: 40
Study 24880692 — intervention group
Group type: COMPARATOR
Intervention: Control Cues
Number of subjects: 40
Study 22996370 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells (DC) loaded with antigens from tumor cells, injected subcutaneously in 500 µg of granulocyte‐macrophage colony stimulating factor, weekly for 3 weeks and then monthly for 5 months.
Number of subjects: 0
Study 22996370 — intervention group
Group type: COMPARATOR
Intervention: Irradiated autologous proliferating tumor cells, injected subcutaneously in 500 µg of granulocyte‐macrophage colony stimulating factor, weekly for 3 weeks and then monthly for 5 months.
Number of subjects: 0
Study 19440172 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-absorbent polymer dressing
Number of subjects: 53
Study 17486281 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil on demand
Number of subjects: 1058
Study 17486281 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of tadalafil three times per week
Number of subjects: 1058
Study 14734376 — intervention group
Group type: EXPERIMENTAL
Intervention: A&E physician present
Number of subjects: 124
Study 14734376 — intervention group
Group type: COMPARATOR
Intervention: A&E physician absent
Number of subjects: 124
Study 11989994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 171
Study 11989994 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 171
Study 9801927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (12,500 U, subcutaneously daily) plus antianginal treatment
Number of subjects: 40
Study 7621660 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by a consumer on the second day of training
Number of subjects: 57
Study 7621660 — intervention group
Group type: COMPARATOR
Intervention: Training by a nonconsumer on the second day of training
Number of subjects: 57
Study 7621660 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by a consumer
Number of subjects: 57
Study 7621660 — intervention group
Group type: COMPARATOR
Intervention: Training by a nonconsumer
Number of subjects: 57
Study 2284220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 12 mg daily
Number of subjects: 3
Study 6108725 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (1-10 microgram)
Number of subjects: 10
Study 6108725 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (2.5-250 ng)
Number of subjects: 10
Study 6108725 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (100 ng-2.5 microgram)
Number of subjects: 10
Study 6108725 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 10
Study 31543351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable glasses
Number of subjects: 379
Study 31543351 — intervention group
Group type: COMPARATOR
Intervention: Standard glasses
Number of subjects: 379
Study 30192907 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextually tailored activity suggestions (walking or antisedentary)
Number of subjects: 44